The acute influence of psilocybin slows down human reaction times and mildly impairs parts of cognition that coordinate behavior. These short-term effects scale with the dose of the drug, highlighting a need for supervision and safety measures while the substance is active in the body. The findings were recently published in the journal Psychopharmacology. Psychedelic substances are increasingly being evaluated for their therapeutic potential in treating conditions like anxiety and depression. As these drugs move toward broader clinical acceptance, researchers are attempting to understand exactly how they alter immediate thinking processes. Cognitive functions, specifically executive functions, are essential mental skills that help people plan, focus attention, remember instructions, and juggle multiple tasks. Executive functions act as a sort of traffic control system for the brain, coordinating basic abilities to achieve a specific goal. Impairments in this system are common across various psychiatric conditions. Observing how psychedelics temporarily alter these domains helps scientists gauge basic safety and the potential side effects of future clinical treatments. P. Yousefi, a researcher at Leiden University, and Morten P. Lietz, …